For traditional pharmaceutical chemical molecules, one of the main limitations is their effects are dependent on the binding affinity with the active sites on the druggable targets. Protein Degraders molecules have broken the limitations to achieve sufficient effects with lower doses even for undruggable proteins. Lots of targets have been studied, such as p38 MAPK kinases, BRD2, and BRD3. As a key part of the Protein Degraders molecules, the small molecule binder of a target protein, also known as warhead, should be carefully designed and selected, especially for targets with different isoforms. Creative Biolabs offers several ready-to-use target ligands to help customers experience the first step of Protein Degraders molecule discovery and we have services to meet requirements.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us